No improvements in CV outcomes at 90 days with human ApoA-1 infusions post-MI Medical Education on ReachMD

Details

Presenters

Comments

Overview
ACC.24 - Michael Gibson shares the results of the AEGIS-II trial, in which infusions of human ApoA-1 - the building block of HDL-c - with CSL112 in the first month after an MI did not improve CV mortality, MI or stroke at 90 days.
Educational information
This video was recorded in response to a presentation at the Congress of the American College of Cardiology (ACC) 2024.
Faculty
Michael Gibson, MD is an interventional cardiologist, cardiovascular researcher & educator. He is the CEO of the combined non-profit Baim and PERFUSE research institutes at Harvard Medical School, Boston, MA, US.
Disclaimer
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Read our summary of the AEGIS-II trial
Release date: 7 april 2024

Presenters

Recommended

Details

Presenters

Comments

Overview
ACC.24 - Michael Gibson shares the results of the AEGIS-II trial, in which infusions of human ApoA-1 - the building block of HDL-c - with CSL112 in the first month after an MI did not improve CV mortality, MI or stroke at 90 days.
Educational information
This video was recorded in response to a presentation at the Congress of the American College of Cardiology (ACC) 2024.
Faculty
Michael Gibson, MD is an interventional cardiologist, cardiovascular researcher & educator. He is the CEO of the combined non-profit Baim and PERFUSE research institutes at Harvard Medical School, Boston, MA, US.
Disclaimer
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Read our summary of the AEGIS-II trial
Release date: 7 april 2024

Presenters

No improvements in CV outcomes at 90 days with human ApoA-1 infusions post-MI